Interleukin-6 and TNF-alpha as biomarkers associated with ACE2 SNPs rs1978124 and rs2074192 in patients type II diabetes mellitus with COVID-19
IL-6 and TNF-alpha as biomarkers associated with ACE2 SNPs rs1978124 and rs2074192 in patients with COVID-19
DOI:
https://doi.org/10.28922/qmj.v21i1.904Keywords:
SARS-CoV2, COVID-19 , diabetes mellitus type 2, Cytokine, ACE2Abstract
Abstract
Background: Diabetics have a unique set of challenges as a result of the current SARS-CoV-2 Coronavirus illness 2019 (COVID-19) epidemic. It predisposes to a particularly severe course of the disease and doubles the risk of dying from COVID-19. Aim: was to study the analysis and comparison of the relationship between polymorphisms and immune cytokines in the pathogenesis of type 2 diabetes in SARS-CoV-2 patients. METHODS: From January 2022 to April 2022, blood samples were drawn from 120 patients were Divided into three groups for a cross-sectional and case-control study admitted to COVID-19 isolation wards, 40 of who were infected with SARS-CoV-2 virus and were mainly diabetic, 40 of who had diabetes only, and 40 control samples. They were randomly selected, with ages ranging from (18-75) years.
Results: The results of the analysis showed that most infections are between the ages of 40-49. Also, it was clearly shown that females were infected more than males, and the comparison between the molecular examination of ACE2 (rs 1978124 and rs2074192) and cytokines, including IL- 6, TNF--?, result in the relationship between the ACE2 (rs1978124) genotype and serum IL-6 levels. for COVID-19 patients with diabetes, SNP TT (162.14± 99.95)compared to the CC genotype and CT, but for Diabetic patients was CC ( 33.11± 50.88), the relationship between the ACE2 (rs1978124) genotype and serum TNF--? levels.was genotype CT( 204.52± 76.64) to COVID-19 patients with diabetes , while Diabetic patients genotype TT(82.08 ± 34.00) . While, the relationship between the ACE2 (rs2074192) genotype and serum IL-6 levels, in COVID-19 patients with diabetes CT ( 193.13± 86.75) compared to the CC and TT genotype,and Diabetic patients were CC(41.63± 54.04) pg/ml compared to TT genotype and CT. and ACE2 (rs2074192) genotype and serum TNF-? levels COVID-19 patients with diabetes CT (172.31± 84.77), Diabetic patients CC (79.92± 36.51). Conclusions: ACE2 is known to be a receptor for COVID-19. Which is expressed in most cells of the human body, an important factor and an exacerbation problem in genetically susceptible individuals. The morbidity and mortality rates of SARS-CoV-2 pneumonia are affected by innate immunity. It was observed through the results that the islets of Langerhans in the pancreas were infected, either with the virus or the cytokine storm, which leads to diabetes type 2 .
References
Wu F., Zhao S., Yu B. , Fan W., Chen Y., Wang W., Zhi-Gang S., et al.,(2020). A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269. https://doi.org/10.1038/s41586-020-2008-3.
Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T., Li P., Zhou Y., Lin Y.F., Duan Q., Luo G., Fan S. , Lu Y., Feng A. , Zhan Y., Liang B., Cai W., Zhang L., Du X., Li L., Shu Y., Zou H. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect . 2020.80:656–665. https://doi.org/10.1016/j.jinf.2020.03.041.
Scialo, F. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung.2020.198, 867–877, DOI: 10.1007/ s00408-020-00408-4 (2020).
Xu, H.,(2020).High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. journal oral science 12, 8, DOI: 10.1038/s41368-020-0074-x (2020).
Chen J., Wang R., Wang M., Wei G.W.. Mutations Strengthened SARS-CoV-2 Infectivity. J. Mol. Biol. 2020a . 432, 5212–5226 . https://doi.org/10.1016/j.jmb.2020.07.009.
World Health Organization.Clinical management of severe acute respiratory infection when COVID-19 is suspected. Updated March 13, 2020. Accessed March 18 . doi: 10.1093/cid/ciaa711.
Yamamoto N., Ariumi Y., Nishida N., Yamamoto R., Bauer G., Gojobori T. et al., SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene. 2020; 758:144944. https:// doi.org/10.1016/j.gene.2020.144944 PMID: 32628976
Mckechnie J.L. & Blish C.A. .The innate immune system: fighting on the front lines or fanning the flames of COVID-19? Cell. Host. Microbe, 27 (2020), pp. 863-869, 10.1016/j.chom.2020.05.009. https://doi.org/10.1016/j.chom.2020.05.009.
Yutaro M., Corby F , Takaharu I , Keisuke S , Makiko M, Nathan N. L. , Philipp A, Krishna M. P , Soon GH, Minsun S, Robert F. ,Padera Jr et al.,(2020). KIM-1/TIM-1 is a receptor for SARSCoV-2 in lung and kidney. medRxiv preprint doi: https://doi.org/10.1101/2020.09.16.20190694
Wang E. Y., Mao T., Klein J., Dai Y., Huck J. D., Jaycox J. R. et al., Diverse functional autoantibodies in patients with COVID-19. Nature.2021. 595(7866), 283–288. https://doi.org/10.1038/s41586-021-03631-y.
Weston S. & Frieman M.B .COVID-19: knowns, unknowns, and questions. mSphere .2020. 5, e00203–20. DOI: https://doi.org/10.1128/msphere.00203-20.
Li M.Y., Li L., Zhang Y., Wang X.S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious Diseases of Poverty 2020 9 45.
Li SF, Gong MJ, Zhao FR, Shao JJ, Xie YL, Zhang YG, Chang H.Y. Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. Cell Physiol. Biochem. 2018, 51, 2377–2396 . https://doi.org/10.1159/000495897.
Dai L, and Gao G.F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 2021.21.73. https://doi.org/10.1038/s41577-020-00480-0.
Mercado N. B.,Zahn R.,Wegmann F. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature .2020.586- 583. https://doi.org/10.1038/s41586-020-2607-z.
Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. DOI 10.12932/AP-200220-0772.
Wang Q., Zhang Y., Wu L., Niu S. , Song C., Zhang Z., Lu G., Qiao C., Hu Y. Yuen K.Y., et al., Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020, 181, 894–904.e9. https://doi.org/10.1016/j.cell.2020.03.045.
Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN J. 2020. doi.org/10.2139/ssrn.3527420.
Park A. and Iwasaki A.Type I and type III interferons–induction, signaling , evasion, and application to combat COVID-19 . Cell. Host. Microbe., 27 (2020), pp. 870 878, 10.1016/j.chom.2020.05.008. https://doi.org/10.1016/j.chom.2020.05.008
Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52(5):731–3.
Ragab H. Salah Eldin M., Taeimah R. , Khattab R., Salem. The COVID-19 cytokine storm; what we know so far, Front. Immunol. 11 (2020) 1446. https://doi.org/10.3389/fimmu.2020.01446.
AL-sailawi H. A., Mudhafar M., Majhool A. A. & Asaad A. Study of Cystatin C as Early Biomarker of Nephropathy in Patients with Type 2 DM and Risk Stratification in Tarnaka Hospital of Hyderabad City in India. Journal of US-China Medical Science.2019.16: 232-41. doi: 10.17265/1548-6648/2019.05.004.
Mudhafar M, Zainol I, Aiza Jaafar CN, Alsailawi HA,and Majhool AA. Two green synthesis methods to prepared nanoparticles of Ag: two sizes and shapes via using extract of M. dubia leaves. Journal of Computational and Theoretical Nanoscience.2020. 17(7): 2882-2889 .
Sette A and Crotty S. Adaptive immunity to SARS-CoV-2 and COVID- 19. Cell .2021.184, 861–880. https://doi.org/10.1016/j.cell.2021.01.007.
Wang Y, Chen Y, Qin Q.Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–76. https://doi.org/10.1002/jmv.25748.
Lagunas-Rangel, F.A.; Chávez-Valencia, V. High IL-6/IFN-? ratio could be associated with severe disease in COVID-19 patients. J. Med. Virol. 2020. doi: 10.1002/jmv.25900.
Gutierrez-Rodelo C., Arellano-Plancarte A., Hernandez-Aranda J., Landa-Galvan H.V., Parra-Mercado G.K., Moreno-Licona N.J., Hernandez-Gonzalez K.D., Catt K.J., Villalobos-Molina R., Olivares-Reyes J.A. Angiotensin II Inhibits Insulin Receptor Signaling in Adipose Cells. Int. J. Mol. Sci. 2022. 23, 6048. https://doi.org/10.3390/ijms23116048.
Abdulrasool M. M., Ruaa K. M., Mays A. D., ALsailawi H. A. & Mudhafar M. Regeneration of Chitosan-Based Adsorbents Used in Heavy Metal Adsorption. Journal of Life Sciences, 2021.15: 1-9. doi: 10.17265/1934-7391/2021.01.002.
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM , Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine & Growth Factor Reviews .2020. 54, 62–75. https://doi.org/10.1016/j.cytogfr.2020.06.001.
Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. (2019). Nat. Rev. Microbiol. 2019.17, 181–192. https://doi.org/10.1038/s41579-018-0118-9.
Eguchi S., Kawai T., Scalia R., Rizzo V. Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology. Hypertension. 2018 May;71(5):804-810. https://doi.org/10.1161/HYPERTENSIONAHA.118.10266.
Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT(2) receptor and tissue injury: therapeutic implications. Curr Hypertens Rep. 2014 Feb;16(2):416. https://doi.org/10.1007/s11906-013-0416-6.
Tay M.Z., Poh C.M., Renia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020. 20, 363–374. DOIhttps://doi.org/10.1038/s41577-020-0311-8.
Hojyo S., Uchida M.,Tanaka K., Hasebe R., Tanaka Y.,Murakami M., Hirano T. How COVID-19 induces cytokine storm with high mortality Inflammation and Regeneration, 40 (2020), p. 37. https://doi.org/10.1186/s41232-020-00146-3.
Chen K., Xiao F., Hu D., Ge W., Tian M., Wang W., Pan P., Wu K., and Wu J. SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-? production. Viruses . 2020 a. 13, 47. https://doi.org/10.3390/v13010047.
Muniyappa R. Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am. J. Physiol. Metab. 2020, 318, E736–E741.
Medina-Enríquez, M.M., Lopez-León, S., Carlos-Escalante, J.A. et al. ACE2: the molecular doorway to SARS-CoV-2. Cell Biosci 10, 148 (2020). doi.org/10.1186/s13578-020-00519-8.
Viveiros A , Rasmuson J,Vu j, Mulvagh SL,Cindy Y. Y. , Norris CM, and Oudit GY.Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. American Journal of Physiology. Heart and Circulatory Physiology 320, H296–H304.2021. doi.org/10.1152/ajpheart.00755.2020.
Ji H., De Souza A, Bajaj B,Zheng W, Xie W, Robert C. Speth and Sandberg K. Sex - specific modulation of blood pressure and the rennin angiotensin system by ACE (Angiotensin-converting enzyme) 2. Hypertension (Dallas, Tex.: 1979) 76, 478–487. doi.org/10.1161/HYPERTENSIONAHA.120.15276.
Jiawei C., Quanlong J., Xian X., Kangping L., Zhengqing Y., Wanyu T. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging cell.2020.Volum 19.Issue 7 ,e 13168 . doi.org/10.1111/acel.13168.
Donato G. , Barbara B. , Maria L. , Paola S. , Giorgio Z. , Veronica T. COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males International. Int. J. Mol. Sci. 2020, 21(10), 3474.doi.org/10.3390/ijms21103474 .
Adeel S. Z., Lindsay S. M., Tova G. et al .Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019. JAMA Neurol. 2020;77(8):1018-1027. doi:10.1001/jamaneurol.2020.2065.
Jie Z., Hao L., Beiwei Y., Min Z., Jianbo Z., Shaobo D., Yaxin G., Yingze Z., Min Li, Sai L. One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents.Clinical Infectious Diseases, Volume 75, Issue 1, 1 July 2022, Pages e1072–e1081. doi.org/10.1093/cid/ciab884 .
Fountain JH , Kaur J, Sarah LL.Physiology, Renin Angiotensin System.National libratory of Medicine. Last Update: March 12, 2023.
Acelajado MC, Zachary HH, Suzanne O. and David A. Calhoun .Treatment of Resistant and Refractory Hypertension.Originally published28 Mar 2019. Research. 2019;124:1061–1070.
https://doi.org/10.1161/CIRCRESAHA.118.312156Circulation
Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine, 76 (2020a), pp. 14-20. doi.org/10.1016/j.ejim.2020.04.037.
Ghafouri S.F., Noroozi R., Omrani M.D., Branicki W., Po?piech E., Sayad A., Pyrc K., ?abaj P.P., Vafaee V., Taheri M., Sanak M. Angiotensin converting enzyme: a review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection Vasc. Pharmacol., 130 (2020), p. 106680 . doi.org/10.1016/j.vph.2020.106680.
Samavati L., Uhal B. ACE2, much more than just a receptor for SARS-COV-2 .Front. Cell. Infect. Microbiol., 10 . p. 317. Volume 10 - 2020 .doi.org/10.3389/fcimb.2020.00317
Farzaneh S., Sahar S.i M., Samira T. ,Morteza G. Jajin, Fatemeh S.et al.,(2023).The impact of ACE2 polymorphisms (rs1978124, rs2285666, and rs2074192) and ACE1 rs1799752 in the mortality rate of COVID-19 in different SARS-CoV-2 variants . Human Genomics.2023. volume 17, Article number: 54 . doi.org/10.1186/s40246-023-00501-8.
Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40:905–19. doi.org/10.1007/s10096-020-04138-6.
Meo SA, Alhowikan A M , Al-Khlaiwi T, Meo I M, Halepoto D M, Iqbal M. et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–9.
Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020; https://doi. org/10.1097/cm9.0000000000000744.
Guo W., Li M. ,DongY., Zhou H.,Zhang Z,Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID19. DiabetesMetabResRev. 2020.doi.org/10.1002/ dmrr.3319 .
Hayrunnisa B, Ömer K, Bilgin O, Riza S. HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism . Journal: J Headache Pain. 2021 Aug 12;22(1):94 . doi.org/10.1186/s10194-021-01306-7.
Zefferino R, Di Gioia S, Conese M. Molecular links between endocrine, nervous and immune system during chronic stress. Brain Behav. 2021.Feb;11(2):e01960. doi: 10.1002/brb3.1960. Epub 2020 Dec 8.
Lisha Y., Iqra I., Jingliang C., Chunli W., Xiaojun T., Asaduzzaman K., Xiaodong F. and Junjiang F.,(2018). Evaluation of amplification refractory mutation system (ARMS) technique for quick and accurate prenatal gene diagnosis of CHM variant in choroideremia. pmcid: pmc5741072 pmid: 29296092 .
Daniel W. W. ,Cross C. Biostatistics: A Foundation for Analysis in the Health Sciences, John Wiley & Sons New York. (2009).
Boehmer TK, DeVies J, Caruso E, van Santen K L, Tang S, Black C L & Gundlapalli AV. Changing age distribution of the COVID-19 pandemic—United States, May–August 2020. Morbidity and Mortality Weekly Report, 69(39), 1404. doi: 10.15585/mmwr.mm6939e1.
Monod M, Blenkinsop A, Xi X, Hebert D, Bershan S, Tietze S, and Ratmann O. Age groups that sustain resurging COVID-19 epidemics in the United States. 2021.Science, 371(6536). DOI: 10.1126/science.abe8372
Manoj K, Shatdal C, Niraj KJ, Bidhata R, Narayan G, Jharana S, Mahmud AK, Pradip C. IMPACT OF COVID-19 PATIENTS WITH DIABETES MELLITUS AND ITS ASSOCIATION WITH CLINICAL OUTCOMES . Journal of Universal College of Medical Sciences . Jul-Dec2022, Vol. 10 Issue 2, p19-22. 4p. No.02 Issue 26 .
Jaffar S.A., Hassan M.A., Jawad I.R. The first 40-days experience and clinical outcomes in the management of coronavirus covid-19 crisis. Single center preliminary study. J Fac Med Baghdad. 2019.61(3): 94-97. DOI: https://doi.org/10.32007/jfacmedbagdad.613,41739.
Esraah Alharris and Dina Saleh .The Pathological Basis for Severe Corona Virus Disease-19 in Diabetic Patients.International Journal of Drug Delivery Technology (2022); DOI: 10.25258/ijddt.12.2.74.
Hanan SAO, Amal SAA, and Ibrahim TA. Medical geo analysis of epidemical curve for emerged Corona epidemic and the suggested strategies to limit its spread. Misan Journal of Academic Studies 2020, Volume 19, Issue 39, Pages 1-11.
Suhail1 HJ, Waleed SM, Hussien YA,and Kadhim SF. Demographic and Epidemiological Characterization of COVID-19 Confirmed Cases in Diwaniya Governorate, 2020 . Latin American Journal of Pharmacy (formerly Acta Farmacéutica Bonaerense) Lat. Am. J. Pharm. 40 (special issue): 44-8 (April 2021).
Bermejo-Martin jf, Milagros G, Almansa R, Micheloud D, Tedim AP, Domínguez-Gil M, Salvador Resino et al.Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.J Critical Care volume 24, Article number: 691 (2020). DOIhttps://doi.org/10.1186/s13054-020-03398-0
Luo Y., Liu C., Guan T., Li Y., Lai Y., Li F. et al. Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang Hypertens. Res., 42 (2019), pp. 681-689 . https://doi.org/10.1038/s41440-018-0166-6.
